Abstracts

Safety of Tenofovir Alafenamide in Individuals With a History of Proximal Renal Tubulopathy on TDF

Background: Proximal renal tubulopathy (PRT, Fanconi syndrome) is an important but uncommon complication of tenofovir disoproxil fumarate (TDF). There are few long-term safety data for tenofovir alafenamide (TAF) in this population. We evaluated the safety of TAF in individuals who experienced treatment-limiting PRT while receiving TDF, and here report the five year outcomes. Methods: Participants…

Dolutegravir-Based Therapy, Diet, Activity & Weight Gain: 48-Week Prospective Cohort in South Africa

Background: Weight gain has been reported among people with HIV (PWH) after transitioning to tenofovir, lamivudine, and dolutegravir (TLD) antiretroviral therapy (ART). However, the contribution of changes in diet and physical activity to weight gain in this population remains poorly understood. We estimated relationships between diet, physical activity, and clinically significant weight gain over 48…

Inflammatory Profile of B/F/TAF, DTG/ABC/3TC, and DTG+F/TAF Over 5 Years and Effects of Viral Blips

Background: Elevated levels of inflammatory markers are linked to increased morbidity/mortality in people with HIV (PWH) and often remain elevated after suppression of HIV-1 replication below the limit of detection by antiretroviral therapy (ART). As new combinations of ART become available, an evaluation of their effects on biomarkers of inflammation are needed. Additionally, it remains…

Residual HIV Viremia Doubles Cardiovascular Disease Incidence Independent of Classic Risk Factors

Background: People living with HIV (PLHIV) have a heightened risk of atherosclerotic cardiovascular diseases (CVD) beyond that explained by traditional risk factors, potentially driven by HIV-related inflammation or other HIV-related factors. Although antiretroviral therapy (ART) should result in undetectable plasma viral loads (VL), some PLHIV show unquantifiable low yet detectable VL via PCR testing (Residual…

Transcriptional Signatures Underlying Cardiovascular Disease in Persons Living With HIV

Background: While statins for primary prevention reduce cardiovascular events, persons with HIV (PWH) have increased risk of cardiovascular disease, likely linked to persistent inflammation. Studies on immune drivers of atherosclerosis among PWH are needed to define additional therapeutic targets. Methods: We obtained thoracic aorta from diseased PWH (n=3) and without HIV (n=14). Autopsies were performed…

Changes in Gut Microbiota Associated With Progression of Atherosclerosis in People With HIV

Background: Variations in gut microbiome might modulate host immune activation and inflammation, potentially linked to increased cardiovascular risk. Our objective was to longitudinally characterize the distinctive features of gut microbiota associated with progression of atherosclerosis measured through carotid artery intima-media thickness (cIMT) in people living with HIV (PLWH). Methods: 96-week, longitudinal study in virologically suppressed…